UNLABELLED: The aim of this study was to examine the effects of bisphosphonate discontinuation on bone metabolism at the spine and hip measured using (18) F-fluoride PET. Bone metabolism at the spine remained stable following discontinuation of alendronate and risedronate at 1 year but increased in the hip in the alendronate group only. INTRODUCTION: Bisphosphonates such as alendronate (ALN) or risedronate (RIS) have persistent effects on spine BMD following discontinuation. METHODS: Positron emission tomography (PET) was used to examine regional bone metabolism in 20 postmenopausal women treated with ALN (n = 11) or RIS (n = 9) for a minimum of 3 years at screening (range 3-9 years, mean 5 years for both groups). Subjects underwent a dynamic scan of the lumbar spine and a static scan of both hips at baseline and 6 and 12 months following treatment discontinuation. (18) F-fluoride plasma clearance (K(i)) at the spine was calculated using a three-compartment model. Standardised uptake values (SUV) were calculated for the spine, total hip, femoral neck and femoral shaft. Measurements of BMD and biochemical markers of bone turnover were also performed. RESULTS: With the exception of a significant decrease in spine BMD in the ALN group, BMD remained stable. Bone turnover markers increased significantly from baseline by 12 months for both study groups. Measurements of K(i) and SUV at the spine and femoral neck did not change significantly in either group. SUV at the femoral shaft and total hip increased significantly but in the ALN group only, increasing by 33.8% (p = 0.028) and 24.0% (p = 0.013), respectively. CONCLUSIONS: Bone metabolism at the spine remained suppressed following treatment discontinuation. A significant increase in SUV at the femoral shaft and total hip after 12 months was observed but for the ALN group only. This study was small, and further clinical studies are required to fully evaluate the persistence of BP treatment.
UNLABELLED: The aim of this study was to examine the effects of bisphosphonate discontinuation on bone metabolism at the spine and hip measured using (18) F-fluoride PET. Bone metabolism at the spine remained stable following discontinuation of alendronate and risedronate at 1 year but increased in the hip in the alendronate group only. INTRODUCTION:Bisphosphonates such as alendronate (ALN) or risedronate (RIS) have persistent effects on spine BMD following discontinuation. METHODS: Positron emission tomography (PET) was used to examine regional bone metabolism in 20 postmenopausal women treated with ALN (n = 11) or RIS (n = 9) for a minimum of 3 years at screening (range 3-9 years, mean 5 years for both groups). Subjects underwent a dynamic scan of the lumbar spine and a static scan of both hips at baseline and 6 and 12 months following treatment discontinuation. (18) F-fluoride plasma clearance (K(i)) at the spine was calculated using a three-compartment model. Standardised uptake values (SUV) were calculated for the spine, total hip, femoral neck and femoral shaft. Measurements of BMD and biochemical markers of bone turnover were also performed. RESULTS: With the exception of a significant decrease in spine BMD in the ALN group, BMD remained stable. Bone turnover markers increased significantly from baseline by 12 months for both study groups. Measurements of K(i) and SUV at the spine and femoral neck did not change significantly in either group. SUV at the femoral shaft and total hip increased significantly but in the ALN group only, increasing by 33.8% (p = 0.028) and 24.0% (p = 0.013), respectively. CONCLUSIONS: Bone metabolism at the spine remained suppressed following treatment discontinuation. A significant increase in SUV at the femoral shaft and total hip after 12 months was observed but for the ALN group only. This study was small, and further clinical studies are required to fully evaluate the persistence of BP treatment.
Authors: P Ravn; M Bidstrup; R D Wasnich; J W Davis; M R McClung; A Balske; C Coupland; O Sahota; A Kaur; M Daley; G Cizza Journal: Ann Intern Med Date: 1999-12-21 Impact factor: 25.391
Authors: C Schiepers; J Nuyts; G Bormans; J Dequeker; R Bouillon; L Mortelmans; A Verbruggen; M De Roo Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: M A Lawson; Z Xia; B L Barnett; J T Triffitt; R J Phipps; J E Dunford; R M Locklin; F H Ebetino; R G G Russell Journal: J Biomed Mater Res B Appl Biomater Date: 2010-01 Impact factor: 3.368
Authors: Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas Journal: J Bone Miner Res Date: 2004-03-29 Impact factor: 6.741
Authors: Morand Piert; Tilman T Zittel; Michael Jahn; Anke Stahlschmidt; Georg A Becker; Hans-Jürgen Machulla Journal: J Nucl Med Date: 2003-01 Impact factor: 10.057
Authors: K E Naylor; M Bradburn; M A Paggiosi; F Gossiel; N F A Peel; E V McCloskey; J S Walsh; R Eastell Journal: Osteoporos Int Date: 2018-03-10 Impact factor: 4.507
Authors: William Raynor; Sina Houshmand; Saeid Gholami; Sahra Emamzadehfard; Chamith S Rajapakse; Björn Alexander Blomberg; Thomas J Werner; Poul F Høilund-Carlsen; Joshua F Baker; Abass Alavi Journal: Curr Osteoporos Rep Date: 2016-08 Impact factor: 5.096
Authors: Gregory Chang; Sean Boone; Dimitri Martel; Chamith S Rajapakse; Robert S Hallyburton; Mitch Valko; Stephen Honig; Ravinder R Regatte Journal: J Magn Reson Imaging Date: 2017-02-06 Impact factor: 4.813
Authors: Abhijit J Chaudhari; William Y Raynor; Ali Gholamrezanezhad; Thomas J Werner; Chamith S Rajapakse; Abass Alavi Journal: PET Clin Date: 2021-01